COMBINATION THERAPY FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

摘要

The present invention relates to use of combination therapy with an anti-CD22 antibody, such as epratuzumab or hRFB4, and another therapeutic agent for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Preferably the therapeutic agent is a chemotherapeutic agent, more preferably vincristine and/or dexamethasone. The combination therapy can induce complete responses in resistant/refractory ALL and may unexpectedly provide an improved MRD, indicative of long-term disease-free survival, in older human ALL patients.